Features of psoriasis treatment with infection COVID-19

Cover Page

Cite item

Full Text

Abstract

Background. Today, one of the difficult tasks in modern dermatology is the management of patients with chronic dermatoses, including psoriasis, due to a new coronavirus infection. The general condition of the patients, as well as concomitant therapy for the underlying disease, may subsequently produce severe side effects and complicate the treatment of concomitant skin pathology in patients in this category.

Aim. The purpose of our study was to optimize the treatment of patients with psoriasis against the background of COVID-19 infection.

Methods. Our study included 34 patients with psoriasis who were hospitalized at the Zangiota Clinical Hospital, specializing in patients with COVID-19 infection from 2020 to 2022. Also, all patients were divided according to the severity of the underlying disease according to the “Temporary recommendations for the management of patients infected with COVID-19”, fifth version of 2020. The severity of the psoriatic process was assessed using the PASI index.

Results. If patients have a psoriatic process, it is more rational to use biological drugs for the treatment of COVID-19 infection due to the absence of exacerbation of the psoriatic process in dynamics.

Conclusion. Treatment of patients with COVID-19 infection with casivirimab + imdevimab showed a positive effect on the dynamics of skin elements and the absence of relapses during three months of observation. While standard therapy for coronavirus infection gives a good regression of skin elements on the 10th day of therapy, after a month there is a progression of the skin process, the appearance of itching and new elements of psoriasis.

About the authors

Umida A. Tashkenbaeva

Tashkent Medical Academy

Email: umida.tashkenbaeva@tma.uz
ORCID iD: 0000-0001-5854-5271
SPIN-code: 7902-5210

MD, Dr. Sci. (Med.), Associate Professor

Uzbekistan, Tashkent

Aziz Sh. Aliev

Tashkent Medical Academy

Author for correspondence.
Email: dr.aziz.1982828282@gmail.com
ORCID iD: 0000-0003-4872-3649
SPIN-code: 6678-2162

MD, Cand. Sci. (Med.)

Uzbekistan, Tashkent

Sanjar A. Usmanaliev

Tashkent Medical Academy

Email: usmanaliyevsanjar@gmail.com
ORCID iD: 0009-0006-5261-4479
Uzbekistan, Tashkent

References

  1. World Health Organization. COVID-19 Weekly epidemiological update — January 17, 2021. URL: https://www.who.int/docs/default-source/coronaviruse/situationreports/weekly_epidemiological_update_23.pdf?sfvrsn=6ac0778_5&download=true (accessed: 19.01.2021).
  2. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20–36.
  3. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036–1045.e9. doi: 10.1016/j.cell.2020.04.026
  4. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect. 2020;80(6):607–613. doi: 10.1016/j.jinf.2020.03.037
  5. Ташкенбаева У.А., Алиев А.Ш., Усманалиев С.А. Встречаемость хронических дерматозов при COVID-19 инфекции. Новости дерматологии и репродуктивного здоровья. 2023;104(4):49–52. [Tashkenbaeva UA, Aliev ASh, Usmanaliev SA. The incidence of chronic dermatoses during COVID-19 infection. Novosti dermatologii I reproduktivnogo zdorovya. 2023;104(4):49–52. (In Russ.)]
  6. Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L, et al. The burden of chronic kidney disease in systemic lupus erythematosus: A nationwide epidemiologic study. Autoimmun Rev. 2019;18(7):733–737. doi: 10.1016/j.autrev.2019.05.011
  7. Silverberg JI, Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol. 2015;135(3):721–8.e6. doi: 10.1016/j.jaci.2014.11.023
  8. Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the COVID-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320–321. doi: 10.1080/09546634.2020.1749545
  9. Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatelli AGC, Di Mercurio M, et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience — Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292–294. doi: 10.1016/j.jaad.2020.04.165
  10. Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I. Biologic therapy for psoriasis during the COVID-19 outbreak: Тhe choice is to weigh risks and benefits. Dermatol Ther. 2020;33(4):e13490. doi: 10.1111/dth.13490
  11. Di Lernia V, Goldust M, Feliciani C. COVID-19 infection in psoriasis patients treated with cyclosporin. Dermatol Ther. 2020;33(4):e13739. doi: 10.1111/dth.13739
  12. Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the northern Italy experience. Br J Dermatol. 2020;183(2):373–374. doi: 10.1111/bjd.19158
  13. Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328–329. doi: 10.1080/09546634.2020.1757605
  14. Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med. 2021;130:104219. doi: 10.1016/j.compbiomed.2021.104219
  15. Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019. JAAD Case Rep. 2020;6(12):1360–1362. doi: 10.1016/j.jdcr.2020.10.013
  16. Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. COVID-19 and exacerbation of psoriasis. Dermatol Ther. 2020;33(4):e13632. doi: 10.1111/dth.13632
  17. Patrick MT, Zhang H, Wasikowski R, Prens EP, Weidinger S, Gudjonsson JE, et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol. 2021;147(3):857–869.e7. doi: 10.1016/j.jaci.2021.01.006

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Clinical forms of psoriasis with COVID-19 infection (n = 34)

Download (204KB)
Indexing metadata

Copyright (c) 2024 Tashkenbaeva U.A., Aliev A.S., Usmanaliev S.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).